Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q2 2022 · 10-Q
Revenue—
Net Income-$12.42M-$12.42MN/M vs Q2 2021 EPS Diluted-$0.44-$0.44N/M vs Q2 2021 Operating Income-$12,584,000N/M Operating Cash Flowderived-$9,117,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
Free Cash Flowderived-$9,170,000N/M ended Jun 30, 2022 · filed Aug 15, 2022 · 46 d after period end